IP Library › Granted Patent US 7,700,777
Granted Patent B2
US 7,700,777 · App. 11/890,880 · Granted Apr 20, 2010

Crystalline forms of a biphenyl compound

Assignee: Theravance, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,777
App. No.
11/890,880
Granted
Apr 20, 2010
Kind
B2
Abstract

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.

Claims (8)

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a crystalline salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester and phosphoric acid in a 1:2 molar ratio characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 15.0±0.2, 19.4±0.2, 21.6±0.2, and 23.7±0.2.

2. The composition of claim 1 , wherein the powder x-ray diffraction pattern comprises diffraction peaks at 2θ values of 6.4±0.2, 7.6±0.2, 8.6±0.2, 13.7±0.2, 15.0±0.2, 19.4±0.2, 21.6±0.2, 22.1±0.2, 22.9±0.2, and 23.7±0.2.

3. The composition of claim 1 , wherein the crystalline salt is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 1 .

4. The composition of claim 1 , wherein the crystalline salt is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 2 .

5. The composition of claim 1 , wherein the crystalline salt contains about 6 weight percent of water.

6. The composition of claim 1 , wherein the crystalline salt is further characterized by a differential scanning calorimetry trace which shows a maximum endothermic heat flow at about 154.5° C.

7. The composition of claim 5 , wherein the crystalline salt contains about 6.23 weight percent of water.

8. The composition of claim 5 , wherein the crystalline salt contains about 6.54 weight percent of water.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA R&D IP, LLC
Reel/Frame 033127/0174 →
Continuity (3)
Continuation 1137144500 · Mar 9, 2006
Provisional Application 6066020800 · Mar 10, 2005
Related Publication 20070298112A1 · Dec 27, 2007